ALGS - Pambiji Buku Bisnis Aligos Therapeutics Inc.

The price trend for Aligos Therapeutics (ALGS), with a metric of 0.03, as shown on the GURU.Markets platform, highlights the risks of failed drug trials and competitive pressure. The business relies on aggressive cost optimization, seeking to attract strategic allies for the transfer of its development rights. The company's stability is based on strict adherence to bioethics and environmental responsibility during drug creation.

ALGS Kapitalisasi Buku Aligos Therapeutics, Inc. (04.07.2022 - 27.10.2026)

Rincian metrik lan analitis perusahaan Aligos (ALGS)

- rega lan prakiraan konsensus rega:

Bagan kurs Aligos Therapeutics|ALGS - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar Aligos Therapeutics Inc.|ALGS - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku Saham Aligos Therapeutics|ALGS - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku aligos.com|ALGS - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Aligos Therapeutics|ALGS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Aligos Therapeutics|ALGS - Utang perusahaan|Utang marang nilai buku Aligos Therapeutics Inc.

Pambiji fundamental:ALGS - Aligos Therapeutics, Inc.

The net asset book value under US GAAP defines the tangible foundation of the business minus all liabilities, allowing an investor to assess the actual intrinsic value of Aligos Therapeutics (ALGS). Analyzing the organization's balance sheet capitalization reveals that current development costs for hepatitis B drugs are already priced in, rendering the asset resilient to volatility provided there are strong clinical results.

Analisis pesaing Aligos Therapeutics

ARWR: Nilai Buku Bisnis|Mirum Pharmaceuticals - Nilai Buku Perusahaan|DVAX (Dynavax Technologies) - Pambiji Buku Bisnis|Nilai Buku Perusahaan Arbutus Biopharma Corporation ABUS|Nilai Aset Bersih Inventiva SA|Gyre Corp (GYRE) - Kapitalisasi Buku|Nilai Akuntansi Perusahaan Assembly Corp (ASMB)|Kapitalisasi Buku GALT (Galectin Therapeutics Inc.)|Genfit SA - Kapitalisasi Buku|Nilai Buku Perusahaan DURECT Corp. (DRRX)|BIVI: Nilai Akuntansi Perusahaan|GLMD (galmedpharma.com) - Nilai Buku Perusahaan|ENDRA Corp (NDRA) - Aset Bersih Perusahaan|HEPA (Hepion Pharmaceuticals Inc.) - Kapitalisasi Buku